GI23, the American Society of Clinical Oncology’s GI Oncology-focused meeting, just finished in San Francisco this January.
In the DocTalk below, broken into four parts, Paltown Scientific Director Dr. Manju George chats with Dr. Cathy Eng, Dr. Anwaar Saeed, Dr. J Joshua Smith, and Dr. Nina Niu Sanford about CRC updates from this meeting.
In part one, Dr. Cathy Eng covers a few interesting results, including a poster on the effect of dropping the 5FU bolus, some results on neoadjuvant therapy for MSS colon cancer, rare subsets of metastatic CRC like those with BRAF mutations & HER2/ERBB2 amplification. Lastly, she talks briefly about new results on the use of ctDNA in colorectal cancer.
Dr. Anwaar Saeed covers a few interesting #GI23 results including the Agenus Bot+Bal trial & its safety profile, RIN trial, IO+TKI trial such as STELLAR 303, other IO+ approaches, a general intro to adoptive cell therapy including engineered TCRs & CART cell approaches. She covered TMB and its use as an IO biomarker. She also talked about machine learning and its use in CRC.
In part three, Dr. Nina Sanford covers a few interesting results including those from NRG GI-002, OPERA & RAPIDO trials & goes over ongoing questions with regard to Total Neoadjuvant Therapy.
In part four, Dr. J Joshua Smith talks about rectal cancer results from #GI23. The last part has Q & A covering many topics.
Dr. Eng: Phase II/III data still pending.
I would like to get data regarding the combo with shp2 or with immunotherapy
Dr. Eng: I am unaware of the Phase I data being reported out yet with SHP2 or with immunotherapy at this time. The AACR meeting is in April, there may be some data reported there. The combo are historically completed with EGFR inhibitors as well.
Answered in the session
Dr. Eng: Hopefully in the next few months. It will be submitted for FDA and EMA and Japanese approval.
The speaker at ASCO was saying may be more important than the current staging system looking at lymph nodes… and that rectal cancer spreads through blood vs lymph nodes.”
Is that a matter of debate among experts? Answered in the session in Part 4
Dr. Eng: Mountaineer tucatinib will only be approved for previously treated. Newly dx’d will be asked to participate on Mountaineer3
Dr. Eng: SUNLIGHT will result in approval in EU and that is the point of the study design. Won’t impact us in the US.
Answered in the session
Dr. Eng: ctDNA is best in stage III and stage IV vs. stage I and II based on prior studies
Answered in the session
Answered in the session
Answered in the session
Answered in the session
Answered in the session
Comment: Further support re: TMB as biomarker? Dr Fakih’s RegoNivo analysis saw no diff in response of TMB >5 vs. <5
Answered in the session
Answered in the session
Dr. Eng: Yes, the trial is built in now with the recommended medication to reduce the incidence of colitis.
Dr. Sanford: Fucoidan sounds so much fancier than brown seaweed.
Dr. Sanford: Yes, I think so.
Dr. Sanford: Yes, they can technically. Would do if RT makes sense in clinical context (i.e. if few mets/oligomet disease)
Answered in the session
Dr. Saeed: Yes, there were some liver metastasis patients that responded to cabozantinib plus durva in the Camilla trial
Answered in the session
Answered in the session
Answered in the session
Answered in the session
Answered in the sessio